Delving into the Latest Updates on Gloriana Therapeutics , Inc. with Synapse

概览

疾病领域	数量

内分泌与代谢疾病	1
神经系统疾病	1

排名前五的药物类型	数量

基因疗法	1

排名前五的靶点	数量

GDNF	1

关联

1

项与 Gloriana Therapeutics , Inc. 相关的药物

CN115348875

专利挖掘

靶点

GDNF

作用机制-

在研机构

Gloriana Therapeutics , Inc.

原研机构

Gloriana Therapeutics , Inc.

在研适应症

突触核蛋白病

非在研适应症-

最高研发阶段药物发现

首次获批国家/地区-

首次获批日期-

100 项与 Gloriana Therapeutics , Inc. 相关的临床结果

登录后查看更多信息

0 项与 Gloriana Therapeutics , Inc. 相关的专利（医药）

登录后查看更多信息

9

项与 Gloriana Therapeutics , Inc. 相关的文献（医药）

2021-01-01·Advances in Experimental Medicine and Biology4区 · 医学

A Review of Techniques for Biodelivery of Nerve Growth Factor (NGF) to the Brain in Relation to Alzheimer’s Disease

4区 · 医学

Review

作者: Behbahani, Homira ; Almqvist, Per ; Lind, Göran ; Mitra, Sumonto ; Wahlberg, Lars ; Eriksdotter, Maria ; Linderoth, Bengt ; Gera, Ruchi

Age-dependent progressive neurodegeneration and associated cognitive dysfunction represent a serious concern worldwide. Currently, dementia accounts for the fifth highest cause of death, among which Alzheimer's disease (AD) represents more than 60% of the cases. AD is associated with progressive cognitive dysfunction which affects daily life of the affected individual and associated family. The cognitive dysfunctions are at least partially due to the degeneration of a specific set of neurons (cholinergic neurons) whose cell bodies are situated in the basal forebrain region (basal forebrain cholinergic neurons, BFCNs) but innervate wide areas of the brain. It has been explicitly shown that the delivery of the neurotrophic protein nerve growth factor (NGF) can rescue BFCNs and restore cognitive dysfunction, making NGF interesting as a potential therapeutic substance for AD. Unfortunately, NGF cannot pass through the blood-brain barrier (BBB) and thus peripheral administration of NGF protein is not viable therapeutically. NGF must be delivered in a way which will allow its brain penetration and availability to the BFCNs to modulate BFCN activity and viability. Over the past few decades, various methodologies have been developed to deliver NGF to the brain tissue. In this chapter, NGF delivery methods are discussed in the context of AD.

2020-12-01·Alzheimer's Research & Therapy2区 · 医学

The cholinergic system in subtypes of Alzheimer’s disease: an in vivo longitudinal MRI study

2区 · 医学

ArticleOA

作者: Almqvist, Per M ; Eriksdotter, Maria ; Teipel, Stefan ; Wahlberg, Lars U ; Ferreira, Daniel ; Machado, Alejandra ; Cavallin, Lena ; Wahlund, Lars-Olof ; Seiger, Åke ; Grothe, Michel J ; Westman, Eric ; Linderoth, Bengt ; Eyjolfsdottir, Helga ; Lind, Göran

AbstractBackgroundThe heterogeneity within Alzheimer’s disease (AD) seriously challenges the development of disease-modifying treatments. We investigated volume of the basal forebrain, hippocampus, and precuneus in atrophy subtypes of AD and explored the relevance of subtype stratification in a small clinical trial on encapsulated cell biodelivery (ECB) of nerve growth factor (NGF) to the basal forebrain.MethodsStructural MRI data was collected for 90 amyloid-positive patients and 69 amyloid-negative healthy controls at baseline, 6-, 12-, and 24-month follow-up. The effect of the NGF treatment was investigated in 10 biopsy-verified AD patients with structural MRI data at baseline and at 6- or 12-month follow-up. Patients were classified as typical, limbic-predominant, hippocampal-sparing, or minimal atrophy AD, using a validated visual assessment method. Volumetric analyses were performed using a region-of-interest approach.ResultsAll AD subtypes showed reduced basal forebrain volume as compared with the healthy controls. The limbic-predominant subtype showed the fastest basal forebrain atrophy rate, whereas the minimal atrophy subtype did not show any significant volume decline over time. Atrophy rates of the hippocampus and precuneus also differed across subtypes. Our preliminary data from the small NGF cohort suggest that the NGF treatment seemed to slow the rate of atrophy in the precuneus and hippocampus in some hippocampal-sparing AD patients and in one typical AD patient.ConclusionsThe cholinergic system is differentially affected in distinct atrophy subtypes of AD. Larger studies in the future should confirm that this differential involvement of the cholinergic system may contribute to subtype-specific response to cholinergic treatment. Our preliminary findings suggest that future clinical trials should target specific subtypes of AD, or at least report treatment effects stratified by subtype.Trial registrationClinicalTrials.gov identifier: NCT01163825. Registered 14 July 2010.

2020-04-01·Current Research in Pharmacology and Drug Discovery

Long-term, stable, targeted biodelivery and efficacy of GDNF from encapsulated cells in the rat and Goettingen miniature pig brain

Article

作者: Kordower, Jeffrey H ; Wahlberg, Lars U ; Paolone, Giovanna ; Bell, William ; Fradet, Tracie ; Emerich, Dwaine F

Delivering glial cell line-derived neurotrophic factor (GDNF) to the brain is a potential treatment for Parkinson's Disease (PD). Here we use an implantable encapsulated cell technology that uses modified human clonal ARPE-19 cells to deliver of GDNF to the brain. In vivo studies demonstrated sustained delivery of GDNF to the rat striatum over 6 months. Anatomical benefits and behavioral efficacy were shown in 6-OHDA lesioned rats where nigral dopaminergic neurons were preserved in neuroprotection studies and dopaminergic fibers were restored in neurorecovery studies. When larger, clinical-sized devices were implanted for 3 months into the putamen of Göttingen minipigs, GDNF was widely distributed throughout the putamen and caudate producing a significant upregulation of tyrosine hydroxylase immunohistochemistry. These results are the first to provide clear evidence that implantation of encapsulated GDNF-secreting cells deliver efficacious and biologically relevant amounts of GDNF in a sustained and targeted manner that is scalable to treat the large putamen in patients with Parkinson's disease.

100 项与 Gloriana Therapeutics , Inc. 相关的药物交易

登录后查看更多信息

100 项与 Gloriana Therapeutics , Inc. 相关的转化医学

登录后查看更多信息